secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-332422
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx's setrusumab fails Phase 3 primary endpoints in OI; expense cuts planned
--------------------------------------------------------------------------------

- Orbit and Cosmic studies did not meet primary endpoint of reducing annualized clinical fracture rate versus comparators.
- Both studies achieved secondary endpoint of significant improvement in bone mineral density (BMD).
- Company plans to implement significant expense reductions; evaluating next steps for the program.
- Safety profile unchanged; no new safety signals observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525332422/0001193125-25-332422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312525332422/rare-20251229.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-332422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer